Low-dose Pfizer-BioNTech vaccine fails in trial on 2 to 5 year olds
Fox News
A low dose of the Pfizer-BioNTech coronavirus vaccine failed to produce an adequate response in children aged two through five years of age.
"The companies will amend the clinical study evaluating the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age," the statement said. "The study will now include evaluating a third dose of 3 µg at least two months after the second dose of the two-dose series to provide high levels of protection in this young age group."
The companies said if the three-dose study is successful, they plan to apply for emergency authorization sometime in the first half of 2022.
More Related News